Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Clinical Trials

7 clinical trials for Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma — RECRUITING · PHASE3
• Pan-tumor MRD Study — RECRUITING
• Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer — RECRUITING · PHASE2
• Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• ​A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585) — OTHER · PHASE3
• A Study of NDI 1150-101 in Patients With Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1

Refine this search